Keybank National Association OH Decreases Position in Illumina, Inc. $ILMN

Keybank National Association OH decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 14.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 339,246 shares of the life sciences company’s stock after selling 55,820 shares during the period. Keybank National Association OH owned about 0.21% of Illumina worth $32,368,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Rise Advisors LLC increased its holdings in Illumina by 173.6% during the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 224 shares in the last quarter. Cullen Frost Bankers Inc. purchased a new stake in shares of Illumina in the second quarter valued at about $41,000. Caitong International Asset Management Co. Ltd grew its position in shares of Illumina by 2,936.8% in the first quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock valued at $46,000 after purchasing an additional 558 shares during the last quarter. Blue Trust Inc. increased its stake in shares of Illumina by 63.1% during the 2nd quarter. Blue Trust Inc. now owns 654 shares of the life sciences company’s stock worth $62,000 after purchasing an additional 253 shares in the last quarter. Finally, WPG Advisers LLC acquired a new position in shares of Illumina during the 1st quarter worth approximately $58,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ILMN has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Illumina in a report on Wednesday, October 8th. Evercore ISI reduced their price objective on Illumina from $135.00 to $132.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 7th. Stephens set a $110.00 price objective on Illumina and gave the company an “overweight” rating in a research note on Monday, August 4th. Barclays boosted their target price on shares of Illumina from $90.00 to $95.00 and gave the company an “underweight” rating in a research note on Thursday, October 2nd. Finally, Daiwa Capital Markets lowered shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 target price on the stock. in a report on Tuesday, August 12th. Five analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $115.25.

Illumina Trading Up 4.2%

Shares of ILMN stock opened at $99.01 on Friday. The firm has a market cap of $15.22 billion, a P/E ratio of 12.53, a PEG ratio of 2.34 and a beta of 1.40. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The firm’s 50-day simple moving average is $97.97 and its 200-day simple moving average is $92.30.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. Illumina’s revenue was up .4% on a year-over-year basis. During the same quarter last year, the firm posted $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, equities analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.